{"entity":{"id":"elizabeth-mittendorf","kind":"person","name":"Elizabeth A. Mittendorf","aka":[],"tldr":"Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy.","summary":"Elizabeth Mittendorf led IMpassion031, showing neoadjuvant atezolizumab plus chemotherapy raises pathological complete response in TNBC regardless of PD-L1 status, and ran the early HER2 peptide vaccine trials. As a breast surgeon she leads Alliance trials asking whether axillary surgery and radiotherapy can be omitted after excellent neoadjuvant response. She directs breast immuno-oncology at Dana-Farber.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mittendorf%20EA%5BAuthor%5D%20breast%20immunotherapy"}],"tags":["tnbc","surgery","immunotherapy"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["checkpoint-inhibitor","sentinel-node"],"targets":[],"drugs":["atezolizumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-research"],"dependsOn":[],"notes":[],"role":"Director, Breast Immuno-Oncology Program, Dana-Farber Brigham Cancer Center","institutionId":"dana-farber","specialisms":["Breast surgical oncology","Immunotherapy","Neoadjuvant trials","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mittendorf%20EA%5BAuthor%5D%20breast%20immunotherapy"}],"papers":[{"title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)31953-X"},{"title":"PD-L1 expression in triple-negative breast cancer","journal":"Cancer Immunology Research","year":2014,"doi":"10.1158/2326-6066.CIR-13-0127"}]},"route":"/people/elizabeth-mittendorf/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"journal":[{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/"}],"trial":[{"id":"impassion031","kind":"trial","name":"IMpassion031","route":"/trials/impassion031/"}]}}